Efficacy and safety of raltegravir for treatment of HIV for 5 years in the benchmrk studies: final results of two randomised, placebo-controlled trials

Eron, Joseph J.; Cooper, David A.; Steigbigel, Roy T.; Clotet, Bonaventura; Gatell, Jose M.; Kumar, Princy N.; Rockstroh, Jurgen K.; Schechter, Mauro; Markowitz, Martin; Yeni, Patrick; Loutfy, Mona R.; Lazzarin, Adriano; Lennox, Jeffrey L.; Strohmaier, Kim M.; Wan, Hong; Barnard, Richard J. O.; Nguyen, Bach-Yen T.; Teppler, Hedy.
Artículo en Inglés | ARCA | ID: arc-11152

Documentos relacionados

  1. Incorrect interpretation of AIMS trial analyses: comment on Mathes et al.'s 'Response to letter …' (HIV Medicine 2014, 15, 383-384).
  2. Persistent Immune Activation in Human Immunodeficiency Virus-Infected Pregnant Women Starting Combination Antiretroviral Therapy After Conception.
  3. Efectividad de intervención educativa en conocimientos sobre VIH y adherencia terapéutica antirretroviral
  4. The triumph of HIV treatment: another new antiretroviral.
  5. Early Infant Treatment: Still a Long Way to Go to Reach Human Immunodeficiency Virus Remission.
  6. HIV infection or HAART therapy: what is the cause of adverse obstetric outcomes.
  7. Advances in HIV Gene Therapy.
  8. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
  9. The clarifying role of time series data in the population genetics of HIV.
  10. Exploration of adaptation process and experience among the HIV/AIDS patients based on the comprehensive task-based adaptation model.